Low costs and opportunities for efficiency: a cost analysis of the first year of programmatic PrEP delivery in Kenya's public sector.


Journal

BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677

Informations de publication

Date de publication:
16 Aug 2021
Historique:
received: 28 04 2020
accepted: 30 07 2021
entrez: 17 8 2021
pubmed: 18 8 2021
medline: 19 8 2021
Statut: epublish

Résumé

In 2017, the Kenyan Ministry of Health integrated provision of pre-exposure prophylaxis (PrEP) into public HIV-1 care clinics as a key component of the national HIV-1 prevention strategy. Estimates of the cost of PrEP provision are needed to inform the affordability and cost-effectiveness of PrEP in Kenya. We conducted activity-based micro-costing from the payer perspective to estimate both the financial and economic costs of all resources and activities required to provide PrEP in Kenya's public sector. We estimated total and unit costs in 2019 United States dollars from a combination of project expense reports, Ministry of Health training reports, clinic staff interviews, time-and-motion observations, and routinely collected data from PrEP recipient files from 25 high-volume HIV-1 care clinics. In the first year of programmatic PrEP delivery in 25 HIV-1 care clinics, 2,567 persons initiated PrEP and accrued 8,847 total months of PrEP coverage, accounting for 2 % of total outpatient clinic visits. The total financial cost to the Ministry of Health was $91,175, translating to an average of $10.31 per person per month. The majority (69 %) of financial costs were attributable to PrEP medication, followed by administrative supplies (17 %) and training (9 %). Economic costs were higher ($188,584 total; $21.32 per person per month) due to the inclusion of the opportunity cost of staff time re-allocated to provide PrEP and a proportional fraction of facility overhead. The vast majority (88 %) of the annual $80,811 economic cost of personnel time was incurred during activities to recruit new clients (e.g., discussion of PrEP within HIV-1 testing and counselling services), while the remaining 12 % was for activities related to both initiation and maintenance of PrEP provision (e.g., client consultations, technical advising, support groups). Integration of PrEP provision into existing public health HIV-1 care service delivery platforms resulted in minimal additional staff burden and low incremental costs. Efforts to improve the efficiency of PrEP provision should focus on reductions in the cost of PrEP medication and extra-clinic demand creation and community sensitization to reduce personnel time dedicated to recruitment-related activities. ClinicalTrials.gov registration NCT03052010 . Retrospectively registered on February 14, 2017.

Sections du résumé

BACKGROUND BACKGROUND
In 2017, the Kenyan Ministry of Health integrated provision of pre-exposure prophylaxis (PrEP) into public HIV-1 care clinics as a key component of the national HIV-1 prevention strategy. Estimates of the cost of PrEP provision are needed to inform the affordability and cost-effectiveness of PrEP in Kenya.
METHODS METHODS
We conducted activity-based micro-costing from the payer perspective to estimate both the financial and economic costs of all resources and activities required to provide PrEP in Kenya's public sector. We estimated total and unit costs in 2019 United States dollars from a combination of project expense reports, Ministry of Health training reports, clinic staff interviews, time-and-motion observations, and routinely collected data from PrEP recipient files from 25 high-volume HIV-1 care clinics.
RESULTS RESULTS
In the first year of programmatic PrEP delivery in 25 HIV-1 care clinics, 2,567 persons initiated PrEP and accrued 8,847 total months of PrEP coverage, accounting for 2 % of total outpatient clinic visits. The total financial cost to the Ministry of Health was $91,175, translating to an average of $10.31 per person per month. The majority (69 %) of financial costs were attributable to PrEP medication, followed by administrative supplies (17 %) and training (9 %). Economic costs were higher ($188,584 total; $21.32 per person per month) due to the inclusion of the opportunity cost of staff time re-allocated to provide PrEP and a proportional fraction of facility overhead. The vast majority (88 %) of the annual $80,811 economic cost of personnel time was incurred during activities to recruit new clients (e.g., discussion of PrEP within HIV-1 testing and counselling services), while the remaining 12 % was for activities related to both initiation and maintenance of PrEP provision (e.g., client consultations, technical advising, support groups).
CONCLUSIONS CONCLUSIONS
Integration of PrEP provision into existing public health HIV-1 care service delivery platforms resulted in minimal additional staff burden and low incremental costs. Efforts to improve the efficiency of PrEP provision should focus on reductions in the cost of PrEP medication and extra-clinic demand creation and community sensitization to reduce personnel time dedicated to recruitment-related activities.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov registration NCT03052010 . Retrospectively registered on February 14, 2017.

Identifiants

pubmed: 34399736
doi: 10.1186/s12913-021-06832-3
pii: 10.1186/s12913-021-06832-3
pmc: PMC8365926
doi:

Substances chimiques

Anti-HIV Agents 0

Banques de données

ClinicalTrials.gov
['NCT03052010']

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

823

Subventions

Organisme : NIMH NIH HHS
ID : MH095507
Pays : United States
Organisme : NIMH NIH HHS
ID : MH118134
Pays : United States
Organisme : Bill and Melinda Gates Foundation (US)
ID : OPP1056051
Organisme : NIH HHS
ID : AI027757
Pays : United States

Informations de copyright

© 2021. The Author(s).

Références

Implement Sci. 2018 Sep 4;13(1):118
pubmed: 30180860
AIDS Res Treat. 2019 May 2;2019:4170615
pubmed: 31186955
Am J Epidemiol. 2015 Nov 15;182(10):848-56
pubmed: 26487343
AIDS. 2015 Sep 24;29(15):2035-44
pubmed: 26355574
PLoS Med. 2011 Nov;8(11):e1001123
pubmed: 22110407
PLoS Med. 2013;10(3):e1001401
pubmed: 23554579
Lancet HIV. 2017 May;4(5):e214-e222
pubmed: 28233660
J Int AIDS Soc. 2015 Jul 20;18(4 Suppl 3):20013
pubmed: 26198348
J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25296
pubmed: 31328443
PLoS One. 2018 Nov 26;13(11):e0207650
pubmed: 30475841

Auteurs

Kathryn Peebles (K)

Department of Epidemiology, University of Washington, Seattle, WA, USA. kpeebles@uw.edu.
International Clinical Research Center, HMC # 359927 325 Ave, WA, 98104, Seattle, USA. kpeebles@uw.edu.

Kenneth K Mugwanya (KK)

Division of Disease Control, School of Public Health, Makerere University, Kampala, Uganda.
Department of Global Health, University of Washington, Seattle, WA, USA.

Elizabeth Irungu (E)

Department of Global Health, University of Washington, Seattle, WA, USA.
Partners in Health and Research Development, Nairobi, Kenya.

Josephine Odoyo (J)

Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.

Elizabeth Wamoni (E)

Partners in Health and Research Development, Nairobi, Kenya.

Jennifer F Morton (JF)

Department of Global Health, University of Washington, Seattle, WA, USA.

Kenneth Ngure (K)

Department of Public and Community Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.

Elizabeth A Bukusi (EA)

Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.

Nelly R Mugo (NR)

Department of Global Health, University of Washington, Seattle, WA, USA.
Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA.

Sarah Masyuko (S)

National AIDS & Sexually Transmitted Infection Control Programme, Ministry of Health, Nairobi, Kenya.

Irene Mukui (I)

National AIDS & Sexually Transmitted Infection Control Programme, Ministry of Health, Nairobi, Kenya.

Jared M Baeten (JM)

Department of Epidemiology, University of Washington, Seattle, WA, USA.
Department of Global Health, University of Washington, Seattle, WA, USA.
Department of Medicine, University of Washington, Seattle, WA, USA.

Ruanne V Barnabas (RV)

Department of Epidemiology, University of Washington, Seattle, WA, USA.
Department of Global Health, University of Washington, Seattle, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH